Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial

29 June 2021 (00:00 - 00:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Marat Fudim

Duke Clinical Research Institute, Durham (United States of America)

13 More presentations in this session

Presentation thumbnail

Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)

Professor G. Felker (Durham, US)

Presentation thumbnail

Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial

Associate Professor C. DeFilippi (Baltimore, US)

Presentation thumbnail

Nurse Intervention for Less Chronic Heart Failure Study

Professor S. Stewart (Fremantle, AU)

Presentation thumbnail

Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.

Professor J. McMurray (Glasgow, GB)

Presentation thumbnail

Telemedical Interventional Management in Heart Failure

Professor F. Koehler (Berlin, DE)

Access the full session

Session thumbnail

Clinical Trial Updates

The Event

Heart Failure 2021

29 June - 1 July 2021

You may be interested in

Congress Presentation

Interactive discussion and Q&A

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - discussion

Congress Presentation

Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources